Tag Archives | biotech portfolios and ETFs

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates

Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]

Continue Reading 0

Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9

Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]

Continue Reading 0

2018 Biotech Sector Watch on Earnings #2: ABBV, ALXN, BMY…Updates VRTX

Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3  triple combination clinical development programs are underway : VX-559 and VX-441 best for 2020 launch as well as pain and sickle cell R&D.  […]

Continue Reading 0

Biotech and Pharma Stocks Await Q1 Earnings But Gene Editing Stocks Sell-Off

Speculative Biotech Stocks Sell-Off in Profit Taking: Gene Editing Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%. Most large caps were in the green with an upgrade from Goldman Sachs helping Merck (MRK) up 2.4% with a bullish story on Keytruda. Amgen (AMGN) offers good […]

Continue Reading 0

Biotechs Stalled and Get No Help From Monday’s Market Moves…Updates

Updates: 4/19/18 GWPH hits $143 new high,  then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for 1st line use of lung cancer drug. Novartis (NVS) shares […]

Continue Reading 0

2018 Large Cap Biopharmaceutical Stocks : First Quarter Performance Update

2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned Abbvie (ABBV) or Vertex Pharmaceuticals (VRTX). Here are some key takeaways: Buy the worst […]

Continue Reading 0

Rayno BioBeat 2018 #2: Biotech Deal Sparks Rally…Update-1

Update-1 …2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech stocks are leaders YTD beating the S&P 500. […]

Continue Reading 0

How Bad Was The Biotech Selloff Last Week?…Updates-2/6

Updates-2… 2/6/18 Biotechs Down With Overall Market Over 5 Days  Closing Prices as of 2/6/18 XBI up 3% at $91.05 down 5.34% over 5 days IBB up 2% at $109.36 down 7.35% over 5 days QQQ up 2.65% at $162.31 down 5.04% over 5 days By now you have read about all the possible reasons […]

Continue Reading 0

Large Cap Biopharmaceuticals: Performance and Metric Update Part I

Large Cap Biopharmaceuticals 2018 Performance after J.P.Morgan Healthcare Conference  Here is an update of Large Cap Biopharmaceuticals Performance over the past 12 months. These numbers will be updated after all 2017 financials have been reported. Note that the IBB is a good pick for Large Cap Biopharma up ~20% YoY. Only ABBV (a Rayno pick) beat […]

Continue Reading 0

2018 J.P.Morgan Healthcare Conference Day One Notes: Weak Start Despite Positive Updates

Weak Start for Biotech Stocks on 1/8/18-Red Screen Day Positive Updates on BIIB CELG GILD etc Biotech ETFs Firm Up about 1.5% Tuesday AM  JPMorgan Healthcare Conference Biotech stocks abruptly sold off at the market open yesterday with the XBI down 2% to the $85.31 level and the IBB down 1.33% to $108.37. Apparently the 9000 […]

Continue Reading 0